Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-12-20

Clinical Trial Update: Trial of Sunitinib for Refractory Malignant Ascites [Phase 2]

View source ↗

Summary

Phase 2 trial update for sunitinib in refractory malignant ascites has been terminated; results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Sunitinib (sunitinib)

Snippet

Sponsor: Milton S. Hershey Medical Center | Conditions: Ascites | Phase 2 | Status: TERMINATED | Results posted: 2017-12-20